(Reuters) -Drugmaker AstraZeneca is drafting a plan to spin off its China business, and listing a separate unit in Hong Kong is being viewed as an option, the Financial Times reported on Sunday. A ...
-
-
Recent Updates
- Best’s Commentary: Shanghai Cross-Border Investment Pilot Unlocks Overseas Growth Potential of China Non-Life Companies
- Anthropic Lobbying Draws Scrutiny Amid China Chip Fight and Jensen Huang Ouster
- House Panel Says China Uses Smuggling and Fraud to Obtain Advanced AI Technology
- House Panel Says China Uses Smuggling and Fraud to Obtain Advanced AI Technology
- House Panel Says China Uses Smuggling and Fraud to Obtain Advanced AI Technology
- House Panel Says China Uses Smuggling and Fraud to Obtain Advanced AI Technology
- House Panel Says China Uses Smuggling and Fraud to Build AI Power
- House Panel Says China Uses Smuggling and Fraud to Build AI Power
- House Panel Says China Uses Smuggling and Fraud to Build AI Power
- House Panel Says China Uses Smuggling and Fraud to Build AI Power
Blogroll